Question · asked by 1 review

FIBRINOGEN: Therapeutic trials: intervention vs inactive control: All‐cause mortality Up to 28 days post‐operatively

FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
FIBRINOGEN: Therapeutic trials: intervention vs inactive Control
All‐cause mortality Up to 46 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia (2018) · Cochrane Headline outcomes only
RR 0.23 [0.05, 1.01]2 studies · 213 participantsHigh

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Pro‐coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia
2018 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.